OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
STTK
Shattuck Labs, Inc.
There isn't enough reported data to score STTK yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
STTK Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
STTK's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
STTK PE Valuation
STTK has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
STTK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| -- | |
| Limited | |
| Low |
Analysts expect STTK's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over STTK on earnings quality, reporting a profit while its opponent remains loss making.
STTK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.56 | +$0.46 |
| Q2 2026 | -$0.56 | +$0.65 |
| Q1 2026 | -$0.68 | +$0.71 |
| Q4 2025 | -$0.82 | +$0.67 |
| Q3 2025 | -$1.02 | +$0.51 |
| Q2 2025 | -$1.21 | +$0.64 |
| Q1 2025 | -$1.39 | +$0.54 |
| Q4 2024 | -$1.49 | +$0.56 |
STTK is still losing money, but far less than before: $0.56 per share over the past year, against $2.43 at its worst in late 2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over STTK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
STTK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $1M | -67% |
| Q3 2024 | $3M | +337% |
| Q2 2024 | $1.6M | +705% |
| Q1 2024 | $1.1M | +1856% |
| Q4 2023 | $714K | +83% |
| Q3 2023 | $686K | +224% |
| Q2 2023 | $200K | +300% |
| Q4 2022 | $390K | -99% |
STTK's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | -1072% | -474 points |
| Q3 2024 | -598% | +3571 points |
| Q2 2024 | -1427% | +9946 points |
| Q1 2024 | -1798% | +36204 points |
| Q4 2023 | -2654% | +4083 points |
| Q3 2023 | -4169% | +7732 points |
| Q2 2023 | -11374% | +43943 points |
| Q1 2023 | -38002% | N/A |
STTK's operating margin was −1072% last quarter, up 1583 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with STTK at up 29%.
STTK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17.5M | -$8.5M |
| Q1 2026 | -$13.4M | -$1.4M |
| Q4 2025 | -$8.5M | +$8.9M |
| Q3 2025 | -$9M | +$7.1M |
| Q1 2025 | -$12M | +$4.1M |
| Q4 2024 | -$17.4M | +$2.1M |
| Q3 2024 | -$16.1M | +$643K |
| Q2 2024 | -$10.9M | +$8M |
STTK has burned cash in almost every quarter: −$48M over the past year, against −$56M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over STTK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
STTK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +17.5M shares |
| 1 year | +154% | +78.8M shares |
| 3 years | +206% | +87.3M shares |
| 5 years | +210% | +87.9M shares |
| Available history | +579% | +111M shares |
STTK has 130M diluted shares, up 154% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
STTK Net Leverage
STTK's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
STTK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.6 | Neutral |
| Stochastic | 10.1 | Oversold |
STTK's weekly RSI is 40 (neutral) and its Stochastic is 10 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
STTK PE vs Healthcare Sector
STTK has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over STTK on trend strength, trading above more of its moving averages.
STTK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.58 | 14% below |
| 20 week MA | $6.43 | 25% below |
| 50 week MA | $5.68 | 15% below |
| 100 week MA | $3.48 | 38% above |
| 200 week MA | $3.90 | 23% above |
STTK has slipped below its 8-, 20- and 50-week averages, though it's still 23% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over STTK on returns for 2026, with the stronger performance.
STTK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.4 | $57.6 | +198% |
| 2021 | $57.6 | $8.90 | -85% |
| 2022 | $8.90 | $2.41 | -73% |
| 2023 | $2.41 | $7.13 | +196% |
| 2024 | $7.13 | $1.24 | -83% |
| 2025 | $1.24 | $3.35 | +170% |
| 2026 YTD | $3.35 | $4.81 | +44% |
STTK's yearly returns have swung widely, from +198% in 2020 to −85% in 2021. It's up 44% so far in 2026.